PMID- 32425434
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1011-6842 (Print)
IS  - 1011-6842 (Linking)
VI  - 36
IP  - 3
DP  - 2020 May
TI  - Safety and Cumulative Incidence of Major Cardiovascular Events with Ticagrelor in 
      Taiwanese Patients with Non-ST-Segment Elevation Myocardial Infarction: A 
      12-Month, Prospective, Phase IV, Multicenter, Single-Arm Study.
PG  - 195-206
LID - 10.6515/ACS.202005_36(3).20191007B [doi]
AB  - BACKGROUND: Ticagrelor, an oral, direct-acting, and reversible P2Y(12) receptor 
      antagonist, inhibits platelet activation and aggregation. This phase IV, 
      single-arm study analyzed the safety and tolerability of ticagrelor in Taiwanese 
      patients with non-ST-segment elevation myocardial infarction (NSTEMI) during 1 
      year of follow-up. METHODS: Patients aged >/= 20 years with an index event of 
      NSTEMI received ticagrelor (180 mg loading and 90 mg doses twice daily 
      thereafter) plus low-dose aspirin (100 mg/day) for up to 1 year. Safety was 
      evaluated according to adverse events (AEs), serious AEs (SAEs), and 
      PLATO-defined bleeding events. The cumulative incidence of major cardiovascular 
      (CV) events including CV death, myocardial infarction, and stroke was also 
      evaluated. RESULTS: The safety population included 108 patients across 13 centers 
      in Taiwan. During treatment, 32 (29.6%) patients had >/= one PLATO-defined bleeding 
      event. Major bleeding events occurred in seven (6.5%) patients with a 
      Kaplan-Meier (KM) estimated event risk [95% confidence interval (CI)] of 7.1% 
      (3.4%-14.4%), including life-threatening bleeding [four (3.7%) patients] and 
      other major bleeding [three (2.8%) patients]. No PLATO-defined fatal bleeding was 
      observed. SAEs were reported in 23 (21.3%) patients. Six (5.6%) patients 
      experienced major CV events during the 1-year follow-up period, with a 
      KM-estimated event risk (95% CI) of 5.6% (2.6%-12.0%). CONCLUSIONS: Ticagrelor 
      for up to 1 year was associated with a low rate of major bleeding events and a 
      low incidence of major CV events in Taiwanese patients with NSTEMI. The overall 
      safety of ticagrelor was in accordance with the known safety profile of 
      ticagrelor.
FAU - Mar, Guang-Yuan
AU  - Mar GY
AD  - Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan.
AD  - College of Health and Nursing, Meiho University, Pingtung, Taiwan.
FAU - Ridderstrale, Wilhelm
AU  - Ridderstrale W
AD  - AstraZeneca Gothenburg, Molndal, Sweden.
FAU - Wei, Jianxin
AU  - Wei J
AD  - AstraZeneca Gothenburg, Molndal, Sweden.
FAU - Liu, Chun-Peng
AU  - Liu CP
AD  - Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan.
AD  - College of Health and Nursing, Meiho University, Pingtung, Taiwan.
LA  - eng
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Acta Cardiol Sin
JT  - Acta Cardiologica Sinica
JID - 101687085
PMC - PMC7220962
OTO - NOTNLM
OT  - Cardiovascular events
OT  - Non-ST-segment elevation myocardial infarction
OT  - P2Y12 inhibition
OT  - Safety
OT  - Taiwan
OT  - Ticagrelor
EDAT- 2020/05/20 06:00
MHDA- 2020/05/20 06:01
PMCR- 2020/05/01
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/20 06:01 [medline]
PHST- 2020/05/01 00:00 [pmc-release]
AID - 10.6515/ACS.202005_36(3).20191007B [doi]
PST - ppublish
SO  - Acta Cardiol Sin. 2020 May;36(3):195-206. doi: 
      10.6515/ACS.202005_36(3).20191007B.